Could a bitter compound provide clues about how to treat asthma? – Boston.com (blog)


Daily Mail

Could a bitter compound provide clues about how to treat asthma?
Boston.com (blog)
Even more bizarre, scientists found them in cells that line the airway, and in the muscles that contract during an asthma attack. Basic scientific research began to suggest that bitter chemicals had potential as a new class of asthma treatment. That's
How foods that leave a bitter taste in the mouth could prevent asthma attacksDaily Mail
UMMS scientists discover new mechanisms for relaxing airways using bitter EurekAlert (press release)
New mechanism for relaxing airways using bitter tasting substancesScience Codex

all 4 news articles »

View full post on asthma – Google News

About 35 percent of children in Tehran province have asthma and allergies – MENAFN.COM

About 35 percent of children in Tehran province have asthma and allergies
MENAFN.COM
Dec 24, 2012 (Menafn – Trend News Agency – McClatchy-Tribune Information Services via COMTEX) –About 35 percent of children in Tehran province have asthma or various allergies, professor of Iran's University of Medical Sciences, Ebrahim Razi said,

and more »

View full post on asthma – Google News

Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study.

Related Articles

Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study.

J Allergy Clin Immunol. 2012 Nov 19;

Authors: Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, Radulovic S, Chan S, Fox A, Turcanu V, Lack G, Learning Early About Peanut Allergy (LEAP) Study Team

Abstract
BACKGROUND: Peanut allergy (PA) is rare in countries in which peanuts are introduced early into infants’ diets. Learning Early About Peanut Allergy (LEAP) is an interventional study aiming to assess whether PA can be prevented by oral tolerance induction. OBJECTIVE: We sought to characterize a population screened for the risk of PA. METHODS: Subjects screened for the LEAP interventional trial comprise the LEAP screening study cohort. Infants were aged 4 to 10 months and passed a prescreening questionnaire. RESULTS: This analysis includes 834 infants (mean age, 7.8 months). They were split into the following: group I, patients with mild eczema and no egg allergy (n = 118); group II, patients with severe eczema, egg allergy, or both but 0-mm peanut skin prick test (SPT) wheal responses (n = 542); group III, patients with severe eczema, egg allergy, or both and 1- to 4-mm peanut wheal responses (n = 98); and group IV, patients with greater than 4-mm peanut wheal responses (n = 76). Unexpectedly, many (17%) in group II had peanut-specific IgE sensitization (?0.35 kU/L); 56% of group III were similarly sensitized. In contrast, none of the patients in group I and 91% of those in group IV had peanut-specific IgE sensitization. Sensitization on skin testing to peanut (SPT response of 1-4 mm vs 0 mm) was associated with egg allergy and severe eczema (odds ratio [OR], 2.31 [95% CI, 1.39-3.86] and 2.47 [95% CI, 1.14-5.34], respectively). Similar associations were observed with specific IgE sensitization. Black race was associated with a significantly higher risk of peanut-specific IgE sensitization (OR, 5.30 [95% CI, 2.85-9.86]). Paradoxically, for a given specific IgE level, black race was protective against cutaneous sensitization (OR, 0.15 [95% CI, 0.04-0.61]). CONCLUSION: Egg allergy, severe eczema, or both appear to be useful criteria for identifying high-risk infants with an intermediate level of peanut sensitization for entry into a PA prevention study. The relationship between specific IgE level and SPT sensitization needs to be considered within the context of race.

PMID: 23174658 [PubMed – as supplied by publisher]

View full post on pubmed: asthma